Nimotop (Nimodipine)

Nimotop (nimodipine) is indicated for conditions affecting cerebral blood vessels where vasospasm risk is high.

• Subarachnoid hemorrhage: prevents delayed cerebral ischemia by reducing cerebral artery spasm.
• Cerebral vasospasm: relaxes constricted cerebral arteries to improve blood flow.
• Cerebrovascular disorders: supports cerebral perfusion in patients with compromised vascular tone.

• Nimodipine selectively blocks L‑type calcium channels on vascular smooth‑muscle cells, especially in cerebral arteries. By inhibiting calcium influx, it reduces smooth‑muscle contraction, leading to vasodilation of intracranial vessels. This effect lowers the incidence of vasospasm and enhances cerebral blood flow without markedly affecting systemic blood pressure, making it suitable for managing post‑hemorrhagic cerebral vascular complications.

Nimotop may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate intensity.
• Hypotension: transient drop in blood pressure.
• Nausea: occasional gastrointestinal upset.
• Flushing: warmth and redness of skin.
• Dizziness: sensation of light‑headedness.
• Peripheral edema: swelling of lower limbs.

Serious or Rare Side Effects

• Severe hypotension: marked blood pressure reduction requiring medical attention.
• Bradycardia: abnormally slow heart rate.
• Allergic reaction: rash, itching, or swelling.
• Hepatotoxicity: elevated liver enzymes.
• Neutropenia: reduced white blood cell count.
• Stevens‑Johnson syndrome: severe skin eruption.

When prescribing Nimotop, clinicians should observe several safety considerations.

• Monitor blood pressure: watch for symptomatic hypotension.
• Assess hepatic function: adjust use in patients with liver impairment.
• Use caution in elderly: increased sensitivity to vasodilatory effects.
• Avoid abrupt discontinuation: may precipitate rebound vasospasm.
• Review concomitant vasodilators: risk of additive hypotension.
• Store at room temperature: keep in original packaging, protect from moisture and light.

Nimotop can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole): increase nimodipine plasma levels.
• Other calcium channel blockers: additive vasodilatory effect leading to severe hypotension.
• Grapefruit juice: may raise drug exposure and risk of adverse events.

Moderate Interactions (Monitor Closely)

• Antihypertensive agents: monitor blood pressure for excessive lowering.
• Diuretics: watch for electrolyte disturbances and volume depletion.
• Beta‑blockers: observe heart rate and blood pressure.
• Anticonvulsants (e.g., carbamazepine): may reduce nimodipine concentrations.
• NSAIDs: potential impact on renal function when combined with vasodilators.